Clinical Trial Result Information

Protocol number
ML17393

Title of Study
A randomised, open-label, multicentre trial evaluating the safety and efficacy of adding amantadine to a genotype-individualised peginterferon alfa-2a plus ribavirin combination therapy in treatment-naïve or relapsing chronic hepatitis C patients

Sponsor
NV Roche SA

Company division
Pharmaceutical

Product name
PEGASYS

Generic name
peginterferon alfa-2a (40KD)

Therapeutic area
Hepatitis C, Chronic

Clinical study summary
This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.

Phase of development
IV

Date of report
To be Published

Click here for the protocol registry listing of this trial.